In 190 patients with haematological malignancies undergoing haploidentical or unrelated donor transplantation, adding sitagliptin to ATG-based prophylaxis lowered grade 2–4 acute GVHD by day 100 (14.7% vs 31.6%; sHR 0.41; P=.005).
RCTn = 190
Qiao et al. Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial